Caplin Point Laboratories Limited (BOM:524742)
2,083.60
-11.90 (-0.57%)
At close: Jun 17, 2025
Caplin Point Laboratories Revenue
In the fiscal year ending March 31, 2025, Caplin Point Laboratories had annual revenue of 19.37B INR with 14.23% growth. Caplin Point Laboratories had revenue of 5.02B in the quarter ending March 31, 2025, with 10.37% growth.
Revenue
19.37B
Revenue Growth
+14.23%
P/S Ratio
8.17
Revenue / Employee
5.69M
Employees
3,406
Market Cap
158.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 19.37B | 2.41B | 14.23% |
Mar 31, 2024 | 16.96B | 2.28B | 15.51% |
Mar 31, 2023 | 14.68B | 1.97B | 15.53% |
Mar 31, 2022 | 12.71B | 2.09B | 19.64% |
Mar 31, 2021 | 10.62B | 1.98B | 22.96% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,646.93B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,729.85B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,429.39B |
Infosys | 1,647.16B |
Life Insurance Corporation of India | 8,901.58B |
Caplin Point Laboratories News
- 4 weeks ago - Caplin Point Q4 results: Revenue up 10.9% YoY to Rs 502.45 crore, Net profit rises 19.8% YoY - Business Upturn
- 5 weeks ago - Caplin Point Laboratories subsidiary receives USFDA approval for Haloperidol Decanoate Injection - Business Upturn
- 2 months ago - Caplin Point subsidiary Caplin Steriles gets USFDA approval for Phytonadione Injectable Emulsion - Business Upturn
- 2 months ago - Caplin Point Laboratories shares jump over 3% after acquiring Neoethicals Chile SpA - Business Upturn
- 4 months ago - Caplin Point subsidiary secures USFDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution - Business Upturn
- 4 months ago - Caplin Point Laboratories Q3 FY25 Results: Revenue up 13% YoY to Rs 493 crore, Net Profit up 17% YoY - Business Upturn
- 4 months ago - Caplin Point Laboratories subsidiary secures USFDA approval for Procainamide Hydrochloride Injection - Business Upturn
- 5 months ago - Caplin Point Laboratories subsidiary gets USFDA nod for Levetiracetam in sodium chloride injection - Business Upturn